Evidence map›Paper›PMID 33037471›Full record

ArticlePharmaceutical research2020

Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle.

Nivedita Shetty, Yiwen Zhang, Heejun Park, Dmitry Zemlyanov, Dishan Shah, Athena He, Patricia Ahn, Tarun Tejasvi Mutukuri, Hak-Kim Chan, Qi Tony Zhou

Open access · greenAbstract readComparative Study
In one paragraph

Article in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nivedita ShettyDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Yiwen ZhangDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Heejun ParkDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Dmitry ZemlyanovBirck Nanotechnology Center, Purdue University, 1205 West State Street, West Lafayette, Indiana, 47907, USA.
Dishan ShahDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Athena HeDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Patricia AhnDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Tarun Tejasvi MutukuriDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Hak-Kim ChanSydney Pharmacy School, The University of Sydney, Camperdown, NSW, 2006, Australia.
Qi Tony ZhouDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA. tonyzhou@purdue.edu.ORCID http://orcid.org/0000-0002-1438-6990
Purdue University West Lafayette · USState Street (United States) · USThe University of Sydney · AU

Funding

Advancing innovative therapies against pandrug-resistant Gram-negative superbugsR01AI146160 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2019 to 2023
$3.2M
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems ApproachR01AI132681 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2017 to 2020
$2.4M
National Institute of Allergy and Infectious Diseases R01AI132681NIAID NIH HHS R01 AI132681NIAID NIH HHS R01 AI146160
6 · The paper itself

Abstract

purposeThis study aims to understand the impact of spray drying nozzles on particle surface composition and aerosol stability.

methodsThe combination formulations of colistin and azithromycin were formulated by 2-fluid nozzle (2 N) or 3-fluid (3 N) spray drying in a molar ratio of 1:1. A 3-factor, 2-level (2

resultsFPF values for the 2 N formulation (72.9 ± 1.9% for azithromycin & 73.4 ± 0.8% for colistin) were higher than those for the 3 N formulation (56.5 ± 3.8% for azithromycin & 55.1 ± 1.6% for colistin) when stored at 20% RH for 1 day, which could be attributed to smaller physical size for the 2 N. There was no change in FPF for both drugs in the 2 N formulation after storage at 75% RH for 90 days; however, there was a slight increase in FPF for colistin in the 3 N formulation at the same storage conditions. Surface enrichment of hydrophobic azithromycin was measured by X-ray photoelectron spectroscopy for both 2 N and 3 N formulations and interactions were studied using FTIR.

conclusionsThe 3-fluid nozzle provides flexibility in choosing different solvents and has the capability to spray dry at higher feed solid concentrations. This study highlights the impact of hydrophobic azithromycin enrichment on particle surface irrespective of the nozzle type, on the prevention of moisture-induced deterioration of FPF for hygroscopic colistin.

Indexed as

Administration, InhalationAerosolsAnti-Bacterial AgentsAzithromycinColistinDrug CompoundingDrug StabilityEquipment DesignHumidityHydrophobic and Hydrophilic InteractionsParticle SizePowdersSolubilitySolventsSurface PropertiesTechnology, PharmaceuticalAerosolsAnti-Bacterial AgentsAzithromycinColistinPowdersSolventsaerosol performancedry powder inhalerspray dryingsurface compositionthree-fluid nozzle

Identifiers

PMID33037471
PMCPMC7647382
OpenAlexW3091894858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.